PubMed Health⌕ Search

Biomedical subjects

Kurt W Grathwohl

Publications and source records attributed to Kurt W Grathwohl.

4 recordsLinked to original sources
PubMed2005

Low-flow transtracheal rescue insufflation of oxygen after profound desaturation.

BACKGROUND: The objective of this study was to determine whether low-flow transtracheal insufflation of oxygen (TRIO) could rescue an animal from profound desaturation. This temporizing maneuver could be useful during cannot-intubate or -ventilate scenarios by resolving hypoxia without the morbidity associated with more invasive procedures. METHODS: Seven swine for a total of 12 runs were studied. Animals were pharmacologically anesthetized, paralyzed, and mechanically ventilated with room air. After disconnection from the ventilator and desaturation to an Spo2 < 50%, low-flow TRIO (2 L/min) was administered for 1 hour. RESULTS: All animals survived and Spo2 increased to greater than 90% in 23 seconds on average. Pao2 (mean, 183 mm Hg) remained elevated throughout the study. Hemodynamic stability was maintained for at least 15 minutes. CONCLUSION: Low-flow TRIO rescued animals from profound hypoxia and maintained oxygenation for at least 1 hour. Low-flow TRIO did not prevent hypercarbia with its subsequent sympathetic activation.

Animals↗
PubMed2003

High-dose inhaled fluticasone and delayed hypersensitivity skin testing.

INTRODUCTION: Systemic steroids have been associated with anergy. Treatment with high-dose inhaled steroids has many documented systemic side effects, including adrenal suppression, reduction in growth velocity, and increased bone metabolism; however, little is known about their effect on delayed-type hypersensitivity (DTH). STUDY OBJECTIVES: The purpose of this study was to determine if a 28-day course of high-dose inhaled fluticasone suppresses DTH to a standard panel of antigens. METHODS: Forty-five healthy, steroid-naïve subjects volunteered for this randomized, double-blinded, placebo-controlled trial. All subjects had baseline DTH assessed by intradermal skin testing to a standard panel of antigens (tetanus, candida, mumps, and tuberculin) read 72 h after placement. Subjects were then randomized to receive placebo or high-dose inhaled fluticasone (880 micro g/d) for 28 days, after which a second DTH panel was performed. A third DTH panel was performed after a 30-day washout period. MEASUREMENTS AND RESULTS: Of the 45 enrolled subjects, 38 subjects completed the study, including 20 subjects in the placebo group and 18 subjects in the drug group. There was no significant difference in the amount of induration between drug and placebo groups for any of the three periods tested. CONCLUSION: Twenty-eight days of treatment with high-dose inhaled fluticasone did not suppress DTH in healthy volunteers.

Administration, Inhalation↗